ZLDPF (Zealand Pharma AS) Risk Assessment


ZLDPF Zealand Pharma AS ZLDPF
62 GF Score
Price $44.86
GF Value $2,429.27
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Zealand Pharma AS Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Zealand Pharma AS is: High Risk: Sensitive to economic or industry trends.

Zealand Pharma AS  (OTCPK:ZLDPF) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Zealand Pharma AS Risk Assessment Related Terms

ZLDPF vs VRTX, REGN, ALNY: Risk Assessment Comparison

For the Biotechnology subindustry, Zealand Pharma AS's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zealand Pharma AS Risk Assessment vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zealand Pharma AS's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Zealand Pharma AS's Risk Assessment falls into.


ZLDPF
62GF Score
Zealand Pharma AS ZLDPF
Risk Assessment is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Zealand Pharma AS (ZLDPF) Overvalued in 2026?

Based on GuruFocus' analysis, Zealand Pharma AS stock appears to be undervalued. The current stock price of $44.86 is trading 98.2% below its estimated GF Value™ of $2,429.27. GuruFocus considers Zealand Pharma AS to be Possible Value Trap.

Key valuation signals for ZLDPF:

  • Risk Assessment:
  • GF Value™: $2,429.27 vs. price of $44.86 (98.2% below fair value)
  • GF Score™: 62/100 with 3 warning signs

No single metric tells the full story. See the ZLDPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zealand Pharma AS Business Description

Address Sydmarken 11, Soborg, DNK, DK-2860
Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.
62GF Score

Get the complete analysis for ZLDPF

Risk Assessment is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$44.86
Price
$2,429.27
GF Value